AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceHealth CareGeographicals
Philadelphia ChromosomePhiladelphiaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveChromosomes, Human, 21-22 and YFusion Proteins, bcr-ablPyrimidinesThiazolesBenzamidesChromosomesPiperazinesBlast CrisisChromosome MappingChromosome AberrationsChromosomes, Human, Pair 22Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeKaryotypingProto-Oncogene Proteins c-bcrLeukemia, Myeloid, Chronic-PhaseLeukemia, Myeloid, Accelerated PhaseChromosomes, Human, Pair 9Genes, ablCytogeneticsTranslocation, GeneticLeukemia, MyeloidProtein Kinase InhibitorsChromosomes, Human, 6-12 and XChromosome DisordersChromosome BandingX ChromosomeSex ChromosomesAntineoplastic AgentsLeukemia, Neutrophilic, ChronicChromosomes, Human, Pair 1Cytogenetic AnalysisChromosomes, HumanProtein-Tyrosine KinasesBone MarrowIn Situ Hybridization, FluorescenceProto-Oncogene Proteins c-ablChromosomes, BacterialChromosome SegregationHobbiesRemission InductionChromosomes, Human, Pair 7Chromosomes, Human, Pair 11Chromosome DeletionGene RearrangementChromosomes, Human, Pair 17Chromosomes, Human, Pair 6Chromosomes, Human, Pair 21Chromosomes, PlantDrug Resistance, NeoplasmChromosomes, FungalMetaphaseOncogenesLeukemia, LymphoidChromosomes, Human, Pair 2Chromosomes, Human, Pair 16Chromosome PairingChromosomes, MammalianChromosomes, Human, Pair 13Chromosomes, Human, Pair 4Chromosomes, Human, Pair 10Base SequenceNeoplasm, ResidualChromosomes, Human, YChromosomes, Human, Pair 8Chromosomes, Human, Pair 19Molecular Sequence DataChromosomes, Artificial, BacterialChromosomes, Human, XChromosomes, Human, 1-3Chromosomes, Human, Pair 12Chromosome PaintingChromosomes, Human, Pair 5Blotting, SouthernChromosomes, Human, Pair 15Precursor B-Cell Lymphoblastic Leukemia-LymphomaInterferon-alphaChromosomes, Human, Pair 14Chromosomes, Human, Pair 18History, 21st CenturyChromosomes, Human, 16-18Prognosissrc-Family KinasesChromosomes, Human, Pair 20Chromosomes, Artificial, YeastChromosomes, Human, 13-15Genetic LinkagePolymerase Chain ReactionChromosome BreakageTreatment OutcomeBone Marrow TransplantationRing ChromosomesProto-OncogenesChromosome InversionGenetic MarkersMutationNeoplastic Stem Cells
SPRYCELNilotinibImatinib mesylateSecond-line dasatinibChemotherapy in Pediatric PatientsPonatinibChronic myeloid leukemia in chronAcute lymphoblaPediatricTKIsLeukemiasTransplantationLeukemiaVersus50MgTranslocationTreatmentPleuralMyeloproliferativeOutcomesPhaseInhibitorNewlyTyrosine kinaseRemissionChromosomalSurvivalBlinatumomabDefectiveRetrospectivePrednisoneMolecularPositiveInductionStudyResponsesGeneClinicalProduct
SPRYCEL12
  • I've Got SPRYCEL ® (dasatinib). (sprycel.com)
  • See how SPRYCEL may help to treat Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML in CP). (sprycel.com)
  • These are generic versions of dasatinib (Sprycel), which has been available in the EU since 2006. (medscape.com)
  • For the multinational Phase III study, known as DASSIN (Dasatinib versus Imatinib Study In treatment-naïve CML patients), 519 newly diagnosed CML patients who had received no prior treatment were randomized to receive either dasatinib, also known as Sprycel ®, 100 milligrams once daily (259 patients), or imatinib, 400 milligrams once daily (260 patients). (mdanderson.org)
  • The European Commission approved Sprycel (dasatinib) to include the treatment of children and adolescents aged 1 year to 18 years with Philadelphia chromosome-positive CML in chronic phase. (pharmalive.com)
  • The NDC Code 0003-0524-11 is assigned to "Sprycel " (also known as: "Dasatinib"), a human prescription drug labeled by "E.R. Squibb & Sons, L.L.C.". The product's dosage form is tablet, and is administered via oral form. (hipaaspace.com)
  • SPRYCEL (dasatinib) is a kinase inhibitor. (hipaaspace.com)
  • SPRYCEL (dasatinib) is indicated for the treatment of adult patients with: 1 newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. (hipaaspace.com)
  • A supplemental biologics license application for dasatinib (Sprycel) for use in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia has been accepted by the FDA. (targetedonc.com)
  • A supplemental biologics license application (sBLA) for dasatinib (Sprycel) for use in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) has been accepted by the FDA. (targetedonc.com)
  • U.S. Food and Drug Administration Accepts Bristol-Myers Squibb’s Application for Sprycel (dasatinib) in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. (targetedonc.com)
  • Sprycel (dasatinib) Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. (targetedonc.com)
Nilotinib4
  • Bcr-Abl fusion protein has constitutively activated Abl tyrosine kinase activity which is responsible for the uncontrolled proliferation in CML The tyrosine kinase inhibitors (TKIs) such as Imatinib, Dasatinib, and Nilotinib are the current first-line treatments approved by the United States Food and Drug Administration (US FDA) for the treatment of the disease. (eurekaselect.com)
  • Bosutinib is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. (cmlsupport.org.uk)
  • The trial is being conducted in Japanese patients suffering from chronic myeloid leukaemia who have failed treatment with dasatinib or nilotinib or with Philadelphia-chromosome positive acute lymphoblastic leukaemia who have failed prior tyrosine kinase inhibitors. (healthcare-digital.com)
  • IM, nilotinib, or dasatinib, with inhibitors of autophagy resulted in near complete elimination of phenotypically and functionally defined CML stem cells. (lu.se)
Imatinib mesylate2
  • A randomized clinical trial is needed to determine whether the second-generation Abl-tyrosine kinase inhibitor dasatinib is more effective than the first-generation inhibitor imatinib mesylate for childhood Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). (nih.gov)
  • To determine whether dasatinib given at a daily dosage of 80 mg/m2 is more effective than imatinib mesylate at a daily dosage of 300 mg/m2 to improve event-free survival of children with Philadelphia chromosome-positive ALL in the context of intensive chemotherapy without prophylactic cranial irradiation. (nih.gov)
Second-line dasatinib2
  • Survival gains associated with second-line dasatinib treatment were identified via retrospective analyses and published clinical outcomes. (ajmc.com)
  • Target responses to first- or second-line dasatinib were met early, and deep molecular responses were observed. (eur.nl)
Chemotherapy in Pediatric Patients1
  • Stephen Hunger, MD , presented an abstract on "Final Results of CA CA180-372/COG AALL1122 Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ All). (chop.edu)
Ponatinib1
  • Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group (Kodama Y et al. (cml-foundation.org)
Chronic myeloid leukemia in chron2
  • Efficacy and safety of dasatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): minimum 24-month follow-up from the DASISION trial [abstract]. (medscape.org)
  • In November 2017, the FDA approved dasatinib for the treatment of pediatric patients with Ph+ chronic myeloid leukemia in chronic phase. (targetedonc.com)
Acute lymphobla1
  • In this article, we present a unique case study of a patient who developed Philadelphia-positive acute lymphoblastic leukaemia (ALL) while receiving adalimumab, a potent monoclonal antibody that specifically binds to TNF-alpha. (bvsalud.org)
Pediatric5
  • However, the presence of the Philadelphia (Ph) chromosome is not sufficiently specific to diagnose CML, since it is also found in acute lymphoblastic leukemia (aka ALL, 25-30% of adult cases and 2-10% of pediatric cases) and occasionally in acute myelogenous leukemia (AML) as well as mixed-phenotype acute leukemia (MPAL). (wikipedia.org)
  • Conclusion In the largest prospective trial to date in children with CML-CP, we demonstrate that dasatinib is a safe, effective treatment of pediatric CML-CP. (eur.nl)
  • This generic is indicated for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy and pediatric patients with newly diagnosed Ph+ ALL in combination with chemotherapy. (medscape.com)
  • In the trial, pediatric patients with newly diagnosed Ph+ ALL received dasatinib added to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone, according to Bristol-Myers Squibb, the manufacturer of the tyrosine kinase inhibitor. (targetedonc.com)
  • The treatment outcomes for adult Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) have improved with the introduction of pediatric protocols. (bvsalud.org)
TKIs1
Leukemias3
  • A phase I study determined suitable dosing for children with Philadelphia chromosome-positive (Ph+) leukemias. (eur.nl)
  • Also recommended for approval were for two generic formulations of dasatinib (Dasatinib Accord and Dasatinib Accordpharma, both from Accord Healthcare) for the treatment of various leukemias. (medscape.com)
  • Dasatinib-related pleural effusion and lymphocytosis rates are different between adult and pediatrc pts with Philadelphia chromosome-positive leukemias: are age and comorbidities only to blame? (cml-foundation.org)
Transplantation1
  • Results from a phase 2 study showed that a 2-step induction regimen involving dasatinib and intensive chemotherapy was associated with high rates of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients younger than 65 years with Philadelphia chromosome-positive (Ph+), newly diagnosed acute lymphoblastic leukemia (ALL), as well as improved 3-year overall survival (OS) rates for those undergoing allo-HSCT compared with those who did not. (cancertherapyadvisor.com)
Leukemia15
  • The Philadelphia chromosome or Philadelphia translocation (Ph) is a specific genetic abnormality in chromosome 22 of leukemia cancer cells (particularly chronic myeloid leukemia (CML) cells). (wikipedia.org)
  • Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. (medscape.org)
  • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. (medscape.org)
  • Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. (medscape.org)
  • Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. (medscape.org)
  • Pleural effusion in patients with chronic-phase chronic myeloid leukemia (CML-CP) who received first-line dasatinib in the DASISION trial: patient characteristics, management, and outcomes [abstract]. (medscape.org)
  • Chronic myeloid leukemia (CML) is a myeloproliferative disease caused due to translocation between chromosome 9 and 22 leading to a chimeric gene product known as Bcr-Abl. (eurekaselect.com)
  • Chronic myelogenous leukemia (CML) that is Philadelphia chromosome positive. (cancer.gov)
  • A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study) Rochester, Minn. This study seeks adult subjects with R/R Ph+ B-precursor ALL. (mayo.edu)
  • 3 Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (hipaaspace.com)
  • Alterations in cellular metabolism after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review (Li C et al. (cml-foundation.org)
  • The treatment regimen for patients with ALL is determined primarily by the Philadelphia chromosome status of the leukemia and the age of the patient. (medscape.com)
  • A 25-year-old woman with a history of acute lymphoblastic leukemia with Philadelphia chromosome (BCR 22q11.2-ABL1 (9q34)) presented with progressively worsening swelling and pain in her left upper eyelid of 3 months' duration. (bvsalud.org)
  • This randomized phase III trial studies how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations. (uchicagomedicine.org)
  • Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL) is a high-risk, aggressive form of acute leukemia, affecting primarily adults and the elderly. (hindawi.com)
Versus1
  • The DASISION study (DASatinib versus Imatinib Study In treatment-Naive CML patients) showed similar results: achieving major CyR by 3 or 6 months was a better predictor of PFS after initial treatment with first-line dasatinib in chronic-phase CML. (medscape.com)
50Mg1
  • Whether you're looking for Dasatinib 50 Mg Tablet, Dasanat 50 (Dasatinib 50mg), Dasatinib Tablets etc, you can explore and find the best products from Tradeindia. (tradeindia.com)
Translocation5
  • This chromosome is defective and unusually short because of reciprocal translocation, t(9;22)(q34;q11), of genetic material between chromosome 9 and chromosome 22, and contains a fusion gene called BCR-ABL1. (wikipedia.org)
  • Some cases are confounded by either a cryptic translocation that is invisible on G-banded chromosome preparations, or a variant translocation involving another chromosome or chromosomes as well as the long arm of chromosomes 9 and 22. (wikipedia.org)
  • The chromosomal defect in the Philadelphia chromosome is a reciprocal translocation, in which parts of two chromosomes, 9 and 22, swap places. (wikipedia.org)
  • The symbol BCR is derived from breakpoint cluster region, a gene which encodes a protein that acts as a guanine nucleotide exchange factor for Rho GTPase proteins Translocation results in an oncogenic BCR-ABL1 gene fusion that can be found on the shorter derivative chromosome 22. (wikipedia.org)
  • Stone, M. Translocation of C-Abl oncogene correlates with the presence of a philadelphia chromosome in chronic myelocytic leukaemia. (eurekaselect.com)
Treatment4
  • Dasatinib is approved for treatment of adults and children with CML-CP. (eur.nl)
  • Dasatinib is also being studied in the treatment of other types of cancer. (cancer.gov)
  • The other 91 patients received 2 years of treatment with dasatinib combined with chemotherapy. (targetedonc.com)
  • In their concluding remarks, the study authors noted that "this study demonstrated [dasatinib]-combined 2-step induction improved pretransplant treatment, which facilitated [allo-HSCT] and resulted in significantly improved survival. (cancertherapyadvisor.com)
Pleural1
  • No dasatinib-related pleural or pericardial effusion, pulmonary edema, or pulmonary arterial hypertension were reported. (eur.nl)
Myeloproliferative1
  • Philadelphia chromosome-negative myeloproliferative neoplasms (Ph- MPN) in children, adolescents, and young adults (AYA) attract attention from hematologists because they are identified more than before due to the recognition and advancement of diagnostic capacity for Ph- MPN. (bvsalud.org)
Outcomes1
Phase2
  • Methods CA180-226/NCT00777036 is a phase II, open-label, nonrandomized prospective trial of patients, 18 years of age receiving dasatinib. (eur.nl)
  • In this pivotal Phase III study, we confirmed that dasatinib gets more patients to high-quality remission faster than imatinib, making it a superior front-line therapy. (mdanderson.org)
Inhibitor2
  • When co‑administering dasatinib, a c‑SRC inhibitor, the partial restoration of lenvatinib sensitivity in the JHH‑7_LR cell line was observed. (spandidos-publications.com)
  • Patients with Philadelphia chromosome-positive (Ph+) ALL receive a tyrosine kinase inhibitor (TKI) in combination with chemotherapy. (medscape.com)
Newly3
  • Although mutation- or pathway-directed targeted therapy (e.g., using tyrosine kinase inhibitors to treat Philadelphia chromosome [Ph]-positive and Phlike B-cell-ALL) is currently available for only a minority of children with ALL, many of the newly identified molecular alterations have led to the exploration of approaches targeting deregulated cell pathways. (haematologica.org)
  • This analysis focused on the allo-HSCT-related end points in a study of patients with newly diagnosed Ph+ ALL treated with a 2-step dasatinib-containing induction regimen. (cancertherapyadvisor.com)
  • Previously reported results demonstrated that both 3-year EFS and 3-year OS were improved for the overall study population of patients with newly diagnosed Ph+ ALL receiving dasatinib-based therapy compared with imatinib-based induction therapy. (cancertherapyadvisor.com)
Tyrosine kinase2
  • This gene is the ABL1 gene of chromosome 9 juxtaposed onto the breakpoint cluster region BCR gene of chromosome 22, coding for a hybrid protein: a tyrosine kinase signaling protein that is "always on", causing the cell to divide uncontrollably by interrupting the stability of the genome and impairing various signaling pathways governing the cell cycle. (wikipedia.org)
  • The Philadelphia chromosome produces an abnormal enzyme (tyrosine kinase), which is responsible for the abnormal growth pattern increased production of the white blood cells in CML. (msdmanuals.com)
Remission1
  • Patients were randomized to receive daily dasatinib (n = 92) or imatinib (n = 97) continuously for the entire duration of ALL therapy from the time of diagnosis made during remission induction to the end of continuation therapy. (nih.gov)
Chromosomal1
  • This arrest is caused by an abnormal expression of genes, often as a result of chromosomal translocations or abnormalities of chromosome number. (medscape.com)
Survival1
  • The 3-year event-free survival rate for the dasatinib combination was 65.5% (95% CI, 57.7 -73.7), and the 3-year overall survival (OS) rate was 91.5% (95% CI, 84.2-95.5), according to results presented at the 2017 ASH Annual Meeting. (targetedonc.com)
Blinatumomab2
  • This trial evaluated the feasibility of combining the TKI dasatinib with prednisone and blinatumomab in older pts with Ph+ ALL. (clevelandclinic.org)
  • This trial demonstrates the feasibility of combining dasatinib and blinatumomab in Ph+ ALL. (clevelandclinic.org)
Defective2
  • However, 30-40 percent of imatinib patients do not achieve confirmed cytogenic complete response (CCyR), or the absence of the defective chromosome that causes the disease, within a year. (mdanderson.org)
  • Secondary endpoints included rate of and times to CCyR and major molecular response (MMR), defined as a level of .1 percent or lower of the defective chromosome, as well as safety. (mdanderson.org)
Retrospective1
  • This retrospective study identified CML patient data from the Surveillance, Epidemiology and End Results registry, dasatinib clinical trials, and insurance claims data sets. (ajmc.com)
Prednisone1
  • 2) intensive consolidation therapy including dasatinib, cyclophosphamide, daunorubicin, vincristine and prednisone, followed by 4 alternating cycles of 2 different consolidation therapy regimens. (cancertherapyadvisor.com)
Molecular1
  • Blood tests, molecular testing, and chromosome analysis are used for diagnosis. (msdmanuals.com)
Positive1
  • 10 Germline variants of IKZF1 are observed in familial B-ALL and immunodeficiency, 16 , 17 and somatic IKZF1 alterations are enriched in Philadelphia chromosome (Ph)-positive, Phlike, and DUX4 -rearranged B-ALL. (haematologica.org)
Induction1
  • 18 years old were treated with continuous daily dasatinib starting at day 15 of induction chemotherapy. (targetedonc.com)
Study1
  • lead study investigator Stephen Hunger, MD, chief of the Division of Oncology and Director of the Center for Childhood Cancer Research at Children’s Hospital of Philadelphia, said in a statement at the time the data were presented at the 2017 ASH Annual Meeting. (targetedonc.com)
Responses1
  • Previous research conducted at MD Anderson found that more patients taking dasatinib were achieving complete responses more quickly than they do on the current standard of care,' said Kantarjian. (mdanderson.org)
Gene1
  • The result is that a fusion gene is created by juxtaposing the ABL1 gene on chromosome 9 (region q34) to a part of the BCR (breakpoint cluster region) gene on chromosome 22 (region q11). (wikipedia.org)
Clinical2
  • This page contains brief information about dasatinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. (cancer.gov)
  • Find Clinical Trials for Dasatinib - Check for trials from NCI's list of cancer clinical trials now accepting patients. (cancer.gov)
Product2
  • The CHMP noted that studies have demonstrated the satisfactory quality of Dasatinib Accord, as well as its bioequivalence to the reference product. (medscape.com)
  • Dasatinib product price in India ranges from 119 to 2,11,538 INR and minimum order requirements from 1 to 500. (tradeindia.com)